期刊文献+

帕利哌酮与利培酮治疗精神分裂症的疗效及对社会功能的影响 被引量:4

Curative effect of paliperidone and risperidone on schizophrenia and its impact on social function
下载PDF
导出
摘要 目的探讨帕利哌酮与利培酮治疗精神分裂症的疗效及对社会功能的影响。方法 2010年12月~2013年12月期间,采样抽取148例精神分裂症患者作为研究对象,并随机分为两组。对照组74例,给予利培酮治疗;实验组74例,给予帕利哌酮治疗。比较两组临床疗效及社会功能评分情况。结果实验组的显效率为93.24%(69/74),远高于对照组的78.38%(58/74),差异有统计学意义(P〈0.01);实验组GQOLI-74与PANSS评分明显优于对照组,组间比较差异有统计学意义(P〈0.01)。结论帕利哌酮与利培酮治疗精神分裂症均有效,但帕利哌酮在改善患者社会功能及生活质量方面疗效更佳,值得临床推广。 Objective To investigate the curative effect of paliperidone and risperidone on schizophrenia and its impact on social function.Methods 148 cases with schizophrenia were were selected as the research object by sampling from Dec, 2010 to Dec, 2013,and they were randomly divided into the control group and the experimental group,with 74 cases in each group.The control group were treated by risperidone,while the experimental group were treated with paliperidone.Then, the clinical effect and social function of two groups were compared.Results The efficiency rate of the experimental group was 93.24% (69/74), much higher than that of the control group which was only 78.38% (58/ 74), so the difference was statistically significant ( P〈0.01).The GQOLI-74 score and PANSS score of the experi- mental group were better than those of the control group, and their differences between two groups had statistical significance( P 〈0.01).Conclusion Both paliperidone and risperidone are effective in the treatment of schizophrenia,but paliperidone has better curative effect in improving the social function and quality of life of patients.Thus,it is worthy of clinical promotion.
出处 《右江医学》 2014年第3期306-309,共4页 Chinese Youjiang Medical Journal
关键词 精神分裂症 帕利哌酮 利培酮 疗效 社会功能 schizophrenia paliperidone risperidone curative effect social function
  • 相关文献

参考文献16

二级参考文献130

  • 1刘俊彪,吴靖华.氯丙嗪、氯氮平、利培酮对首发精神分裂症患者糖代谢、血脂和体重的影响[J].中国神经精神疾病杂志,2004,30(4):293-295. 被引量:41
  • 2郭春梅,司天梅,舒良.精神分裂症的性别差异[J].国际精神病学杂志,2006,33(4):199-202. 被引量:15
  • 3常秀华,刘龙发.小剂量利培酮治疗老年期精神分裂症临床观察[J].中国老年学杂志,2007,27(14):1421-1421. 被引量:3
  • 4Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition[J]. Am J Psychiatry, 2004, 161 (2) : 1 -56.
  • 5Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia [ J]. Can J Psychiatry, 2005, 50 (1):7-57.
  • 6Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia[ J ]. Drags, 1994, 48(2) : 253 -273.
  • 7Revill P, Serradell N, Bolos J. Paliperidone: antipsychotie agent treatment of bipolar disorder dual dopamine D2/5 - HT2A receptor antagonist[ J ]. Drugs Future, 2006, 31 (7) : 579 - 584.
  • 8Herbert YM, William VB, Isaax FN, et al. Efficacy and tolerability of oral paliperidone extended- release tablets in the treatment of acute schizophrenia: pooled data from three 6 - week, placebo- controlled studies [ J]. J Clin Psychiatry, 2008, 69(5) : 817 -829.
  • 9Tzimos A, Lramer M, Ford L, et al. A six - week placebo - controlled study on the safety and tolerability of flexible doses of oral paliperidone extended - release tablets in the treatment of schizophrenia in elderly patients [ C ]. 159^th Annual Meeting of the American Psychiatry Association, 2006, 183.
  • 10Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended - release tablets : a 6 - week placebo - controlled trial[ J]. Schizophrenia Research, 2007, 90( 1 ) : 147 - 161.

共引文献192

同被引文献38

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部